{"id":3399,"date":"2017-07-20T11:22:13","date_gmt":"2017-07-20T09:22:13","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/5-biotech-presse-lounge-in-entspannter-atmosphaere\/"},"modified":"2020-07-14T12:33:56","modified_gmt":"2020-07-14T10:33:56","slug":"5th-biotech-press-lounge-in-a-relaxed-atmosphere","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/5th-biotech-press-lounge-in-a-relaxed-atmosphere\/","title":{"rendered":"5th Biotech Press Lounge in a relaxed atmosphere"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

5th Biotech Press Lounge in a relaxed atmosphere<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]July 2017[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”3391″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”](f.l.t.r.) Dr. Markus Enzelberger, Interims-Forschungsvorstand\u00a0 \/ Interim CSO, MorphoSys AG<\/em>, Dr. Christian Jung, \u00adPrincipal, Wellington Partners<\/em>,
\nJulia Gro\u00df, Journalistin \/ Journalist, Euro am Sonntag<\/em>, Dr. Christian Schetter, Gesch\u00e4ftsf\u00fchrer \/ CEO, Rigontec GmbH<\/em>, Dr. Peter Hanns Zobel, Gesch\u00e4ftsf\u00fchrer \/ CEO, F\u00f6rdergesellschaft IZB mbH<\/em>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]A relaxed atmosphere at the 5th Biotech Press Lounge at the IZB: MorphoSys, Rigontec and Wellington Partners provided insights into their current research as well as an update on the life science venture capital market.<\/strong><\/p>\n

More than 100 guests from the life sciences and venture capital sector participated in the fifth biotech press lounge in the Faculty Club at the Innovation and Start-Up Center for Biotechnology (IZB) on May 11, 2017. In the opening speech Dr. Peter Hanns Zobel said: \u201cHere, we are sitting door to door with top scientists and Nobel Prize winners. The dynamics of the location continue unabated. Over the last half year, three new start-ups have become established at the IZB, namely Immunic, SciMab and MetaHeps.\u201d Julia Gross \u00advon Euro on Sunday moderated the talks of the speakers Dr. Markus Enzelberger (interim CSO of MorphoSys AG), Dr. Christian \u00adJung (Principal of Wellington Partners) and Dr. Christian Schetter (CEO of Rigontec GmbH).<\/p>\n

\u201cThe Biotech Press Lounge and the IZB are an excellent places to benefit from mutual exchange and inspiration. MorphoSys AG also benefited from these synergies during its time at the IZB between1997 and 1999, and has now developed into a leading company for therapeutic antibodies,\u201d said Dr. Enzelberger. In his talk he provided a glimpse into the history of developing the antibody Guselkumab. This drug candidate is being developed by the MorphoSys partner company Janssen for the treatment of psoriasis. The U.S. Food and Drug Administration (FDA) has approved Tremfya™ (guselkumab)\u00a0 on the 13th of July 2017.<\/p>\n

[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner][vc_single_image image=”3395″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Christian Jung
\nPrincipal, Wellington Partners[\/vc_column_text][vc_single_image image=”3393″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Julia Gro\u00df
\nJournalist, Euro am Sonntag
\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_column_text]<\/p>\n

\u201cThe great popularity for the Biotech Press Lounge shows that the organizers have hit a nerve: the network meeting has established itself as a coveted branch meeting.\u201c<\/h6>\n

Julia Gro\u00df, Journalist
\nEuro am Sonntag<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591796940077{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Immunotherapy is currently a highly relevant topic and will also continue to gain importance in the area of cancer therapy. In his short speech, Dr. Christian Schetter, CEO of Rigontec GmbH, explained how the new technology of the company is spectacularly combating tumors with the help of the immune system. He pointed out the enormous potential for establishing a new standard in the immunotherapy market. Rigontec recently announced administering the lead drug candidate to the first patient in a Phase I \/ II clinical trial.<\/p>\n

As part of his talk \u201cUpdate to the Life Science Venture Capital Market\u201d, Dr. Christian Jung, Principal at Wellington Partners, once again emphasized the importance of venture capital-financed companies as drivers for innovation in the health care market. \u201cEstablished companies increasingly rely on purchasing from VC-financed companies to replenish their product portfolio. Nine out of the 10 best-selling medications in 2015 were originally developed by biotechs,\u201d according to Jung.<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_column_text]<\/p>\n

\u201cI particularly enjoy this event because members of research and industry come together in one place, which facilitates an easy exchange of ideas.\u201d<\/h6>\n

Prof. Andr\u00e9 Br\u00e4ndli
\nBiomedical Centre LMU Munich<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” css=”.vc_custom_1591796934586{margin-top: 21px !important;}”][vc_column_inner][vc_single_image image=”3389″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Markus Enzelberger
\nInterims CSO
\nMorphoSys AG[\/vc_column_text][vc_single_image image=”3387″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Christian Schetter
\nCEO
\nRigontec GmbH[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_column_text]<\/p>\n

\u201cI think this is a great event to network. I also enjoy the structure of the event and that the talks are presented without slides, as well as the interesting Q&A sessions. I\u2019m sure I will be back next time.\u201d<\/h6>\n

Julia Hofmann
\nHead of Investor Relations & PR,
\nMedigene AG<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” css=”.vc_custom_1594722408786{margin-top: 21px !important;margin-bottom: 45px !important;}”][vc_column_inner][vc_single_image image=”3385″ img_size=”full”][vc_single_image image=”3383″ img_size=”full”][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n